社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
First Tracks Biotherapeutics Inc(TRAX)
盘后
37.00
0.87
+2.41%
19:59 EDT
36.13
+1.76
+5.12%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
富国银行首次覆盖First Tracks Biotherapeutics，给予“超配”评级及30美元目标价
美股速递 · 06-08
富国银行首次覆盖First Tracks Biotherapeutics，给予“超配”评级及30美元目标价
First Tracks Biotherapeutics公布2026年第一季度财务业绩并更新业务进展
美股速递 · 05-15
First Tracks Biotherapeutics公布2026年第一季度财务业绩并更新业务进展
First Tracks Biotherapeutics公司：售股股东或可出售高达10.5股普通股 - SEC文件披露
美股速递 · 05-09
First Tracks Biotherapeutics公司：售股股东或可出售高达10.5股普通股 - SEC文件披露
Piper Sandler首予First Tracks Biotherapeutics增持评级 目标价54美元
美股速递 · 05-04
Piper Sandler首予First Tracks Biotherapeutics增持评级 目标价54美元
Leerink Partners首次覆盖First Tracks Biotherapeutics 给予"跑赢大盘"评级及46美元目标价
美股速递 · 04-24
Leerink Partners首次覆盖First Tracks Biotherapeutics 给予"跑赢大盘"评级及46美元目标价
巴克莱首予First Tracks Biotherapeutics增持评级 目标价40美元
美股速递 · 04-22
巴克莱首予First Tracks Biotherapeutics增持评级 目标价40美元
公司概况
公司名称
First Tracks Biotherapeutics Inc
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
- -
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
First Tracks Biotherapeutics, Inc.于2025年10月17日根据特拉华州法律注册成立，是AnaptysBio，Inc.的直接全资子公司。该公司是一家临床阶段的生物技术公司，专注于为自身免疫性疾病和炎症性疾病提供创新的免疫学疗法。
06-23
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
05-14
季度报告
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05-14
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
05-08
招股说明书
Form S-1 - General form for registration of securities under the Securities Act of 1933
Form S-1 - General form for registration of securities under the Securities Act of 1933
04-22
超过5%披露
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
04-20
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
04-18
员工持股计划
Form S-8 - Securities to be offered to employees in employee benefit plans
Form S-8 - Securities to be offered to employees in employee benefit plans
04-03
重要事件披露
Form 8-K - Current report
Form 8-K - Current report
分时
5日
日
周
月
数据加载中...
最高
36.92
今开
34.50
量比
0.27
最低
33.53
昨收
34.37
换手率
1.42%
热议股票
{"pagemeta":{"title":"First Tracks Biotherapeutics Inc(TRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供First Tracks Biotherapeutics Inc(TRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"First Tracks Biotherapeutics Inc,TRAX,First Tracks Biotherapeutics Inc股票,First Tracks Biotherapeutics Inc股票老虎,First Tracks Biotherapeutics Inc股票老虎国际,First Tracks Biotherapeutics Inc行情,First Tracks Biotherapeutics Inc股票行情,First Tracks Biotherapeutics Inc股价,First Tracks Biotherapeutics Inc股市,First Tracks Biotherapeutics Inc股票价格,First Tracks Biotherapeutics Inc股票交易,First Tracks Biotherapeutics Inc股票购买,First Tracks Biotherapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"First Tracks Biotherapeutics Inc(TRAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供First Tracks Biotherapeutics Inc(TRAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"news","symbol":"TRAX","data":{"stockData":{"symbol":"TRAX","market":"US","secType":"STK","nameCN":"First Tracks Biotherapeutics Inc","latestPrice":36.13,"timestamp":1784145600000,"preClose":34.37,"halted":0,"volume":486881,"hourTrading":{"tag":"盘后","latestPrice":37,"preClose":36.13,"latestTime":"19:59 EDT","volume":16697,"amount":607928.25,"timestamp":1784159960122,"change":0.87,"changeRate":0.02408,"amplitude":0.02408},"delay":0,"changeRate":0.05120744835612468,"floatShares":34219639,"shares":34748800,"eps":-4.854211,"marketStatus":"已收盘","change":1.76,"latestTime":"07-15 16:00:00 EDT","open":34.5,"high":36.92,"low":33.53,"amount":17317164.31155,"amplitude":0.098633,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.854211,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784188800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.37,"preHourTrading":{"tag":"盘前","latestPrice":34.52,"preClose":34.37,"latestTime":"09:25 EDT","volume":19,"amount":656.73994,"timestamp":1784121900068,"change":0.15,"changeRate":0.004364,"amplitude":0.025022},"postHourTrading":{"tag":"盘后","latestPrice":37,"preClose":36.13,"latestTime":"19:59 EDT","volume":16697,"amount":607928.25,"timestamp":1784159960122,"change":0.87,"changeRate":0.02408,"amplitude":0.02408},"volumeRatio":0.27259,"impliedVol":0.8763,"impliedVolPercentile":0.8444},"tweetData":null,"newsData":{"listData":[{"id":"1160045773","title":"富国银行首次覆盖First Tracks Biotherapeutics，给予“超配”评级及30美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1160045773","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160045773?lang=zh_cn&edition=full","pubTime":"2026-06-08 18:46","pubTimestamp":1780915574,"startTime":"0","endTime":"0","summary":"富国银行分析师团队启动了对生物制药公司First Tracks Biotherapeutics Inc.的研究覆盖，并给予其股票“超配”评级。该行同时设定了30美元的目标股价，预示着分析师认为该公司股票在当前水平上具有显著的上行潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102003350","title":"First Tracks Biotherapeutics公布2026年第一季度财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1102003350","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102003350?lang=zh_cn&edition=full","pubTime":"2026-05-15 04:16","pubTimestamp":1778789777,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics Inc. 近日公布了其截至2026年第一季度的财务业绩，并向市场同步更新了公司最新的业务动态。此次发布涵盖了公司在关键研发项目上的推进情况、管线布局的调整以及未来的战略规划，旨在为投资者提供全面的运营视角。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137960030","title":"First Tracks Biotherapeutics公司：售股股东或可出售高达10.5股普通股 - SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1137960030","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137960030?lang=zh_cn&edition=full","pubTime":"2026-05-09 04:40","pubTimestamp":1778272801,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会的一份文件显示，First Tracks Biotherapeutics Inc的现有售股股东，可能将出售高达10.5股公司普通股。\n这份文件揭示了股东潜在的股份出售计划，相关信息已按监管要求进行备案。具体细节可在相关SEC文件中查阅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166118707","title":"Piper Sandler首予First Tracks Biotherapeutics增持评级 目标价54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1166118707","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166118707?lang=zh_cn&edition=full","pubTime":"2026-05-04 11:36","pubTimestamp":1777865787,"startTime":"0","endTime":"0","summary":"投行Piper Sandler首次覆盖生物技术公司First Tracks Biotherapeutics，给予\"增持\"评级，并设定54美元的目标股价。\n该评级反映出分析师对该公司研发管线前景的乐观预期。目标价的设定基于对其创新疗法的估值评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150338315","title":"Leerink Partners首次覆盖First Tracks Biotherapeutics 给予\"跑赢大盘\"评级及46美元目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1150338315","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150338315?lang=zh_cn&edition=full","pubTime":"2026-04-24 18:10","pubTimestamp":1777025447,"startTime":"0","endTime":"0","summary":"生物制药新锐First Tracks Biotherapeutics Inc迎来资本市场重要里程碑——知名投行Leerink Partners今日发布首份覆盖报告，给予该公司\"跑赢大盘\"的积极评级。这份覆盖报告的发布，标志着专业投资机构对First Tracks Biotherapeutics研发管线与商业前景的正式认可。Leerink Partners作为医疗健康领域的顶尖投行，其评级动向往往引发市场高度关注。随着创新药企融资环境逐步改善，具备差异化技术平台的First Tracks Biotherapeutics有望借助资本市场的东风，加速其前沿疗法的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148679757","title":"巴克莱首予First Tracks Biotherapeutics增持评级 目标价40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1148679757","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148679757?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:39","pubTimestamp":1776854355,"startTime":"0","endTime":"0","summary":"巴克莱集团宣布首次覆盖生物制药公司First Tracks Biotherapeutics，并给予\"增持\"评级。该机构同时设定了40美元的目标股价，显示出对该公司未来发展潜力的积极展望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAX"],"isVideo":false,"video":null,"gpt_icon":0}],"currentPage":1,"bottom":true},"noticeData":{"listData":[{"cdn_pdf":false,"hasAttachments":true,"id":"21419673","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526277504-TRAX","pdf_url":"","pub_time":1782158716000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"TRAX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/2091349/0001193125-26-277504-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 1.01: Entry into a Material Definitive Agreement","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"8-K","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526277504/trax-20260615.htm","primary":true,"translateUrl":"","linkName":"trax-20260615.htm","type":"8-K","id":"NTFILEGyRibri6M7QrkUHL","market":"us","size":44337}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-06-23 04:05","pubTimestamp":1782158716,"title_zh":"Form 8-K - Current report","summary_en":"Item 1.01: Entry into a Material Definitive Agreement","summary_zh":"项目1.01：订立重大最终协议","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21260301","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526224190-TRAX","pdf_url":"","pub_time":1778731200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","symbol":"TRAX","title":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","titleType":"季度报告","type":"usFinancials","url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/0001193125-26-224190-index.htm","us_notice_code":"Form 10-Q","us_title_en":"Form 10-Q - Quarterly report [Sections 13 or 15(d)]","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"10-Q","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-20260331.htm","primary":true,"translateUrl":"","linkName":"trax-20260331.htm","type":"10-Q","id":"NTFILECZc5CALSqCJP3Kmb","market":"us","size":1959429},{"description":"EX-10.3","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-ex10_3.htm","primary":false,"translateUrl":"","linkName":"trax-ex10_3.htm","type":"EX-10.3","id":"NTFILEB4HU4rKusAMAzfMM","market":"us","size":154604},{"description":"EX-10.4","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-ex10_4.htm","primary":false,"translateUrl":"","linkName":"trax-ex10_4.htm","type":"EX-10.4","id":"NTFILE9BcihuA1vHxhHEk6","market":"us","size":133739},{"description":"EX-10.5","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-ex10_5.htm","primary":false,"translateUrl":"","linkName":"trax-ex10_5.htm","type":"EX-10.5","id":"NTFILE4YMhJQehSmXYdevg","market":"us","size":133432},{"description":"EX-10.6","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-ex10_6.htm","primary":false,"translateUrl":"","linkName":"trax-ex10_6.htm","type":"EX-10.6","id":"NTFILECEoFhcjuk4fp5qWR","market":"us","size":133733},{"description":"EX-10.7","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-ex10_7.htm","primary":false,"translateUrl":"","linkName":"trax-ex10_7.htm","type":"EX-10.7","id":"NTFILEFYhAMGUdqmExMHYB","market":"us","size":500634},{"description":"EX-10.8","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-ex10_8.htm","primary":false,"translateUrl":"","linkName":"trax-ex10_8.htm","type":"EX-10.8","id":"NTFILEBkiJBUnSKknFwyYy","market":"us","size":21285},{"description":"EX-31.1","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-ex31_1.htm","primary":false,"translateUrl":"","linkName":"trax-ex31_1.htm","type":"EX-31.1","id":"NTFILE8TUGCWn5nP8xNwKD","market":"us","size":12239},{"description":"EX-31.2","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-ex31_2.htm","primary":false,"translateUrl":"","linkName":"trax-ex31_2.htm","type":"EX-31.2","id":"NTFILEJ6updBQPFcaTXjVZ","market":"us","size":11998},{"description":"EX-32.1","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-ex32_1.htm","primary":false,"translateUrl":"","linkName":"trax-ex32_1.htm","type":"EX-32.1","id":"NTFILEFVoUDj9VnjQeKdjd","market":"us","size":9042},{"description":"EX-32.2","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/trax-ex32_2.htm","primary":false,"translateUrl":"","linkName":"trax-ex32_2.htm","type":"EX-32.2","id":"NTFILEG1ZJiTxCnpPsVjd8","market":"us","size":9044},{"description":"GRAPHIC","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224190/img256966574_0.jpg","primary":false,"translateUrl":"","linkName":"img256966574_0.jpg","type":"GRAPHIC","id":"NTFILEGiK37uUaBVdgxeQ9","market":"us","size":69188}],"type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Quarterly Report","us_type":"usFinancials","us_type_zh":"财务报告","earn_infos":[],"event_type":"important_notice","event_name":"季度报告","pubTime":"2026-05-14 12:00","pubTimestamp":1778731200,"title_zh":"Form 10-Q - Quarterly report [Sections 13 or 15(d","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21260288","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526224124-TRAX","pdf_url":"","pub_time":1778731200000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"TRAX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/0001193125-26-224124-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/trax-ex99_1.htm","primary":true,"translateUrl":"","linkName":"trax-ex99_1.htm","type":"EX-99.1","id":"NTFILEFGna8YTHUSQnb5PH","market":"us","size":157321},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526224124/trax-20260514.htm","primary":false,"translateUrl":"","linkName":"trax-20260514.htm","type":"8-K","id":"NTFILEE7n5M2cWoTFzXqJw","market":"us","size":44330}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-05-14 12:00","pubTimestamp":1778731200,"title_zh":"Form 8-K - Current report","summary_en":"Item 2.02: Results of Operations and Financial Condition;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第2.02项：经营业绩和财务状况；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21233720","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526214778-TRAX","pdf_url":"","pub_time":1778212800000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form S-1 - General form for registration of securities under the Securities Act of 1933","symbol":"TRAX","title":"Form S-1 - General form for registration of securities under the Securities Act of 1933","titleType":"招股说明书","type":"usProspectusesRegistrations","url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/0001193125-26-214778-index.htm","us_notice_code":"Form S-1","us_title_en":"Form S-1 - General form for registration of securities under the Securities Act of 1933","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"S-1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570ds1.htm","primary":true,"translateUrl":"","linkName":"d53570ds1.htm","type":"S-1","id":"NTFILEGkdAcwafyepxc6us","market":"us","size":1745291},{"description":"EX-2.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex21.htm","primary":false,"translateUrl":"","linkName":"d53570dex21.htm","type":"EX-2.1","id":"NTFILEAFjSwCxEriiqEd4s","market":"us","size":367370},{"description":"EX-3.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex31.htm","primary":false,"translateUrl":"","linkName":"d53570dex31.htm","type":"EX-3.1","id":"NTFILE71GZbgtFcGL1V8r1","market":"us","size":28416},{"description":"EX-3.2","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex32.htm","primary":false,"translateUrl":"","linkName":"d53570dex32.htm","type":"EX-3.2","id":"NTFILE2HJt4Ffjze38cxaS","market":"us","size":169917},{"description":"EX-5.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex51.htm","primary":false,"translateUrl":"","linkName":"d53570dex51.htm","type":"EX-5.1","id":"NTFILE6c5A4Z3SJ8MQTdj5","market":"us","size":9620},{"description":"EX-10.1","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex101.htm","primary":false,"translateUrl":"","linkName":"d53570dex101.htm","type":"EX-10.1","id":"NTFILE6nvbuioL4B2kgcSo","market":"us","size":153673},{"description":"EX-10.2","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex102.htm","primary":false,"translateUrl":"","linkName":"d53570dex102.htm","type":"EX-10.2","id":"NTFILEE7NRexh3CitzHQVq","market":"us","size":127333},{"description":"EX-10.3","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex103.htm","primary":false,"translateUrl":"","linkName":"d53570dex103.htm","type":"EX-10.3","id":"NTFILE49xkMN18bzqm3std","market":"us","size":58214},{"description":"EX-10.4","seq":9,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex104.htm","primary":false,"translateUrl":"","linkName":"d53570dex104.htm","type":"EX-10.4","id":"NTFILEFbzFga7zKzCJaCbn","market":"us","size":204426},{"description":"EX-10.5","seq":10,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex105.htm","primary":false,"translateUrl":"","linkName":"d53570dex105.htm","type":"EX-10.5","id":"NTFILEGbdxboyuPbpPuWX8","market":"us","size":128414},{"description":"EX-10.6","seq":11,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex106.htm","primary":false,"translateUrl":"","linkName":"d53570dex106.htm","type":"EX-10.6","id":"NTFILEG65M37SodoeLUu5s","market":"us","size":62560},{"description":"EX-10.7","seq":12,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex107.htm","primary":false,"translateUrl":"","linkName":"d53570dex107.htm","type":"EX-10.7","id":"NTFILE5fy1GEGa3sqTaUy5","market":"us","size":51672},{"description":"EX-23.1","seq":13,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dex231.htm","primary":false,"translateUrl":"","linkName":"d53570dex231.htm","type":"EX-23.1","id":"NTFILEDz4mBcgaFNXmBLkh","market":"us","size":1289},{"description":"EX-FILING FEES","seq":14,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/d53570dexfilingfees.htm","primary":false,"translateUrl":"","linkName":"d53570dexfilingfees.htm","type":"EX-FILING FEES","id":"NTFILEBpJE5YoFiA8UQePq","market":"us","size":18261},{"description":"GRAPHIC","seq":15,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/g53570g09p09.jpg","primary":false,"translateUrl":"","linkName":"g53570g09p09.jpg","type":"GRAPHIC","id":"NTFILE3wVJKWW5ZZZcvJS8","market":"us","size":147569},{"description":"GRAPHIC","seq":16,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/g53570g13p13.jpg","primary":false,"translateUrl":"","linkName":"g53570g13p13.jpg","type":"GRAPHIC","id":"NTFILE4eFXTwpt8Fdq6Cxg","market":"us","size":117471},{"description":"GRAPHIC","seq":17,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526214778/g53570g93p93.jpg","primary":false,"translateUrl":"","linkName":"g53570g93p93.jpg","type":"GRAPHIC","id":"NTFILE8jUpYzws8NYVQNUq","market":"us","size":113790}],"type_name":"招股注册","type_name_en":"Recruitment Registration","titleTypeEn":"Public Prospectus","us_type":"usProspectusesRegistrations","us_type_zh":"招股注册","earn_infos":[],"event_type":"important_notice","event_name":"招股说明书","pubTime":"2026-05-08 12:00","pubTimestamp":1778212800,"title_zh":"Form S-1 - General form for registration of securities under the Securities Act of 1933","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21066207","market":"us","labels":[],"media":"sec.gov","original_id":"AN93583626000209-TRAX","pdf_url":"","pub_time":1776830400000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","symbol":"TRAX","title":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","titleType":"超过5%披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/2091349/000093583626000209/0000935836-26-000209-index.htm","us_notice_code":"Form SCHEDULE 13G","us_title_en":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1587114/000093583626000209/xslSCHEDULE_13G_X02/primary_doc.xml","primary":true,"translateUrl":"","linkName":"primary_doc.html","type":"SCHEDULE 13G","id":"NTFILEAtarupToE4amCw14","market":"us","size":0},{"description":"","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/1587114/000093583626000209/ex991.htm","primary":false,"translateUrl":"","linkName":"ex991.htm","type":"EX-99.1 AGREEMENT","id":"NTFILE2886MuN4u7GjZgbC","market":"us","size":3948}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Beneficial Ownership Change","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"超过5%披露","pubTime":"2026-04-22 12:00","pubTimestamp":1776830400,"title_zh":"Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21039677","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526164328-TRAX","pdf_url":"","pub_time":1776657600000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"TRAX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm","us_notice_code":"Form 8-K","us_title_en":"Item 1.01: Entry into a Material Definitive Agreement;\nItem 2.01: Completion of Acquisition or Disposition of Assets;\nItem 3.02: Unregistered Sales of Equity Securities;\nItem 3.03: Material Modifications to Rights of Security Holders;\nItem 5.01: Changes in Control of Registrant;\nItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers;\nItem 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year;\nItem 8.01: Other Events;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-2.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703dex21.htm","primary":true,"translateUrl":"","linkName":"d78703dex21.htm","type":"EX-2.1","id":"NTFILEESRWvpMcid371TUF","market":"us","size":367298},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703d8k.htm","primary":false,"translateUrl":"","linkName":"d78703d8k.htm","type":"8-K","id":"NTFILECQwMKDaDXoJjZYe3","market":"us","size":134696},{"description":"EX-3.1","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703dex31.htm","primary":false,"translateUrl":"","linkName":"d78703dex31.htm","type":"EX-3.1","id":"NTFILE5MGUiese5MbFiu93","market":"us","size":28410},{"description":"EX-3.2","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703dex32.htm","primary":false,"translateUrl":"","linkName":"d78703dex32.htm","type":"EX-3.2","id":"NTFILE4zRb6YRJrcaY3uxk","market":"us","size":169888},{"description":"EX-10.1","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703dex101.htm","primary":false,"translateUrl":"","linkName":"d78703dex101.htm","type":"EX-10.1","id":"NTFILEDrsd1oD16Bua9AuP","market":"us","size":153647},{"description":"EX-10.2","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703dex102.htm","primary":false,"translateUrl":"","linkName":"d78703dex102.htm","type":"EX-10.2","id":"NTFILE56yArjqHcxPXEByg","market":"us","size":128391},{"description":"EX-99.1","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703dex991.htm","primary":false,"translateUrl":"","linkName":"d78703dex991.htm","type":"EX-99.1","id":"NTFILEGyJzNGKqKjwxwdGS","market":"us","size":7304}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-04-20 12:00","pubTimestamp":1776657600,"title_zh":"Form 8-K - Current report","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"21040060","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526161758-TRAX","pdf_url":"","pub_time":1776459720000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form S-8 - Securities to be offered to employees in employee benefit plans","symbol":"TRAX","title":"Form S-8 - Securities to be offered to employees in employee benefit plans","titleType":"员工持股计划","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/2091349/0001193125-26-161758-index.html","us_notice_code":"Form S-8","us_title_en":"Form S-8 - Securities to be offered to employees in employee benefit plans","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"S-8","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526161758/trax-20260417.htm","primary":true,"translateUrl":"","linkName":"trax-20260417.htm","type":"S-8","id":"NTFILEEWzySwUWjWqrpuu4","market":"us","size":173835},{"description":"EX-5.1","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526161758/trax-ex5_1.htm","primary":false,"translateUrl":"","linkName":"trax-ex5_1.htm","type":"EX-5.1","id":"NTFILEm9byPYbRGpp5tSpM","market":"us","size":16973},{"description":"EX-23.2","seq":3,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526161758/trax-ex23_2.htm","primary":false,"translateUrl":"","linkName":"trax-ex23_2.htm","type":"EX-23.2","id":"NTFILE8Nb41u3RsmdWvHTM","market":"us","size":2626},{"description":"EX-FILING FEES","seq":4,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526161758/trax-exfiling_fees.htm","primary":false,"translateUrl":"","linkName":"trax-exfiling_fees.htm","type":"EX-FILING FEES","id":"NTFILEBF5smrk8yG6k8pTa","market":"us","size":23600},{"description":"GRAPHIC","seq":5,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526161758/img241242223_0.jpg","primary":false,"translateUrl":"","linkName":"img241242223_0.jpg","type":"GRAPHIC","id":"NTFILE7MwtU6ehtKCp6t8Q","market":"us","size":107609}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Employee Stock Ownership","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"员工持股计划","pubTime":"2026-04-18 05:02","pubTimestamp":1776459720,"title_zh":"Form S-8 - Securities to be offered to employees in employee benefit plans","summary_en":"","summary_zh":"","notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":false,"hasAttachments":true,"id":"20961884","market":"us","labels":[],"media":"sec.gov","original_id":"AN119312526140835-TRAX","pdf_url":"","pub_time":1775173238000,"showTitleType":true,"size":0,"source":"sec_us","summary":"Form 8-K - Current report","symbol":"TRAX","title":"Form 8-K - Current report","titleType":"重要事件披露","type":"usAnnouncement","url":"https://www.sec.gov/Archives/edgar/data/2091349/0001193125-26-140835-index.html","us_notice_code":"Form 8-K","us_title_en":"Item 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","attachments":[{"description":"EX-99.1","seq":1,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526140835/d111394dex991.htm","primary":true,"translateUrl":"","linkName":"d111394dex991.htm","type":"EX-99.1","id":"NTFILEF3dAymhxvx5sbUSz","market":"us","size":1714406},{"description":"8-K","seq":2,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526140835/d111394d8k.htm","primary":false,"translateUrl":"","linkName":"d111394d8k.htm","type":"8-K","id":"NTFILEAUQMQTSGjRUGMmoq","market":"us","size":29182},{"description":"GRAPHIC","seq":6,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526140835/g55540g00t01.jpg","primary":false,"translateUrl":"","linkName":"g55540g00t01.jpg","type":"GRAPHIC","id":"NTFILE66rggBXzVwukEciW","market":"us","size":705124},{"description":"GRAPHIC","seq":7,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526140835/g55540g00t02.jpg","primary":false,"translateUrl":"","linkName":"g55540g00t02.jpg","type":"GRAPHIC","id":"NTFILE7cvj8iZ2b1Fp6UZ9","market":"us","size":662760},{"description":"GRAPHIC","seq":8,"linkUrl":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526140835/g55540g00t03.jpg","primary":false,"translateUrl":"","linkName":"g55540g00t03.jpg","type":"GRAPHIC","id":"NTFILE3LuxF2C9Y4VcbTvR","market":"us","size":674911}],"type_name":"交易披露","type_name_en":"Transaction Related","titleTypeEn":"Major Issues Report","us_type":"usAnnouncement","us_type_zh":"交易披露","earn_infos":[],"event_type":"important_notice","event_name":"重要事件披露","pubTime":"2026-04-03 07:40","pubTimestamp":1775173238,"title_zh":"Form 8-K - Current report","summary_en":"Item 7.01: Regulation FD Disclosure;\nItem 9.01: Financial Statements and Exhibits","summary_zh":"第7.01项：法规FD披露；项目9.01：财务报表和附件","notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":true},"companyData":{"profile":{"stockEarnings":[{"period":"1week","weight":0.7376},{"period":"1month","weight":0.9484},{"period":"3month","weight":0.4},{"period":"6month","weight":0.7185},{"period":"ytd","weight":0.7185}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0741},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.2033},{"period":"ytd","weight":0.1025}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"First Tracks Biotherapeutics, Inc.于2025年10月17日根据特拉华州法律注册成立，是AnaptysBio，Inc.的直接全资子公司。该公司是一家临床阶段的生物技术公司，专注于为自身免疫性疾病和炎症性疾病提供创新的免疫学疗法。","exchange":"NASDAQ","name":"First Tracks Biotherapeutics Inc","nameEN":"First Tracks Biotherapeutics Inc"},"aProfile":null}}}